Valuation: Damora Therapeutics, Inc.

Market Cap 1.8B 1.58B 1.47B 1.35B 2.53B 174B 2.58B 17.54B 6.84B 84.81B 6.74B 6.59B 294B P/E 2026 *
-15.3x
P/E 2027 * -14.1x
Enterprise Value 1.35B 1.19B 1.11B 1.02B 1.91B 131B 1.94B 13.22B 5.16B 63.9B 5.08B 4.97B 222B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.38%
Yield 2026 *
-
Yield 2027 * -
1 day-2.73%
1 week-3.54%
Current month+12.15%
1 month+27.16%
3 months+14.75%
6 months+13.24%
Current year+26.77%
1 week 28.25
Extreme 28.25
34.89
1 month 21.69
Extreme 21.69
34.89
Current year 16.5
Extreme 16.5001
34.89
1 year 2.45
Extreme 2.45
38.33
3 years 2.01
Extreme 2.01
92.5
5 years 2.01
Extreme 2.01
118.75
10 years 2.01
Extreme 2.01
449.75
Manager TitleAgeSince
Chief Executive Officer 55 29/03/2026
Director of Finance/CFO - 30/04/2026
Chief Tech/Sci/R&D Officer 60 04/01/2026
Director TitleAgeSince
Chairman 40 22/03/2026
Director/Board Member 42 09/11/2025
Director/Board Member 41 09/11/2025
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Sell

General Counsel

-245 0.0004%
01/05/26 Other

Chief Financial Officer

312,535 0.5077%
30/03/26 Free

Chief Executive Officer

2,000,000 3.3200%
Change 5-day change 1-year change 3-year change Capi.($)
-2.73%-3.54%+668.64%-49.49% 1.8B
+1.23%+0.35%+51.62%+87.98% 55.92B
+5.09%+6.24%+63.15%+62.06% 56.67B
+0.25%+0.55%-19.67%-15.22% 23.28B
+0.72%-0.05%+3.84%+409.54% 23.28B
-1.48%+4.65%+29.65%-4.56% 20.54B
-0.37%+0.71%+31.36%-31.61% 17.78B
-1.44%+5.88%+32.80%+545.36% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
+1.22%-0.05%+22.58%+182.63% 13.99B
Average +0.02%+0.78%+104.81%+147.61% 24.38B
Weighted average by Cap. +1.23%+3.13%+48.01%+132.63%

Financials

2026 *2027 *
Net sales - -
Net income -117M -103M -95.4M -87.74M -165M -11.31B -167M -1.14B -445M -5.51B -438M -429M -19.13B -144M -127M -118M -108M -203M -13.98B -207M -1.41B -550M -6.82B -542M -530M -23.65B
Net Debt -443M -389M -362M -333M -624M -42.88B -635M -4.33B -1.69B -20.92B -1.66B -1.63B -72.56B -326M -287M -267M -245M -460M -31.61B -468M -3.19B -1.24B -15.42B -1.23B -1.2B -53.49B
Logo Damora Therapeutics, Inc.
Damora Therapeutics Inc, formerly Galecto, Inc, is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. It offers a multiple programs including asset, DMR-001, an investigational monoclonal antibody therapy targeting mutCALR. DMR-001 was designed to exclusively bind to mutCALR with exquisite selectivity, potency, and extended half-life, with potential to enable convenient, infrequent subcutaneous dosing.
Employees
7
Date Price Change Volume
23/07/26 US$29.17 -2.73% 488,959
22/07/26 US$29.99 -9.09% 587,259
21/07/26 US$32.99 0.00% 436,637
20/07/26 US$32.99 +4.80% 350,606
17/07/26 US$31.48 +4.10% 489,023
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
29.17USD
Average target price
43.38USD
Spread / Average Target
+48.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMRA Stock